TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04959474

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05986864

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SKG0106
Description: SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SKG0106
Description: SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SKG0106
Description: SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product
Study: NCT04321915

Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of neuroinflammation markers in autism spectrum desorder
Description: This analysis permit to reveal the integrity of the blood-brain barrier (BBB) which is affected in autism spectrum desorder.
Study: NCT04785573

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mastiha oil
Description: 1 soft gel capsule of Mastiha oil every day for 3 months
Study: NCT06132906

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthognathic surgery (lefort1)
Description: 1. All patients will be treated under general anesthesia.~2. The surgical field will be scrubbed with povidone-iodine surgical scrub solution, followed by draping of the patient with sterile towels exposing only the area of surgery.~3. The surgical procedure of Le Fort I osteotomy will be performed which can be summarized as follows:~   1. External reference marking~  2. Incision and subperiosteal dissection~  3. Maxillary osteotomy~  4. Pterygomaxillary disjunction,~  5. Septal, vomerine, and lateral nasal osteotomies~  6. Down fracture~  7. Mobilization of the maxilla~  8. Application of stent in one group and the locating guide in the other group.~  9. Maxillary fixation~  10. Occlusal evaluation~  11. Wound debridement and closure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthognathic surgery (lefort1)
Description: 1. All patients will be treated under general anesthesia.~2. The surgical field will be scrubbed with povidone-iodine surgical scrub solution, followed by draping of the patient with sterile towels exposing only the area of surgery.~3. The surgical procedure of Le Fort I osteotomy will be performed which can be summarized as follows:~   1. External reference marking~  2. Incision and subperiosteal dissection~  3. Maxillary osteotomy~  4. Pterygomaxillary disjunction,~  5. Septal, vomerine, and lateral nasal osteotomies~  6. Down fracture~  7. Mobilization of the maxilla~  8. Application of stent in one group and the locating guide in the other group.~  9. Maxillary fixation~  10. Occlusal evaluation~  11. Wound debridement and closure
Study: NCT05674890

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SmartSystem VR Headset perimeter
Description: Patients will undergo visual field testing with the head-mounted SmartSystem VR Headset perimeter.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SmartSystem VR Headset perimeter
Description: Patients will undergo visual field testing with the head-mounted SmartSystem VR Headset perimeter.
Study: NCT06508489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR443579
Description: Pharmaceutical form: Powder for solution for infusion Route of administration: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Pharmaceutical form :Film coated tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Pharmaceutical form: Lyophilized powder for suspension for injection Route of administration: intravenous or subcutaneous
Study: NCT05590988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tablet-based training
Description: Each task is performed for one minute, followed by a 2-minute break. After the task has been performed three times, there is a 5-minute break. The training block is then carried out twice more. This means that three blocks are carried out for each therapy unit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ergotherapeutic training
Description: A task is performed for one minute at a time, followed by a 2-minute break. Once three rounds have been completed, there is a 5-minute break. As in the intervention group, there are a total of three training blocks.
Study: NCT05009394

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Muscle Reinnervation (TMR)
Description: Surgical procedure used to rewire injured proximal nerves to motor nerves directly innervating an otherwise redundant target muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regenerative Peripheral Nerve Interface (RPNI)
Description: Surgical procedure where the the nerve is split into fascicles and wrapped in free muscle grafts.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard neuroma treatment, neuroma excision, and muscle burying
Description: Surgical procedure where the neuroma is excised and the nerve stump is buried in an adjacent deep muscle.
Study: NCT06519149

Intervention type: DEVICE
Intervention: Slow Wave UASD
Description: An oral appliance for the treatment of OSA and snoring
Study: NCT05382936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-901
Description: Patients took study medication daily, with dosage based on their assigned cohort and regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-901
Description: Patients took study medication daily, with dosage based on their assigned cohort and regimen.
Study: NCT05756608

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-FAPI and 18F-AlF-FAPI PET-MR
Description: Hybrid Cardiac PET-MR with 68Ga-FAPI and 18F-AlF-FAPI radiotracer

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-FAPI and 18F-AlF-FAPI PET-MR
Description: Hybrid Cardiac PET-MR with 68Ga-FAPI and 18F-AlF-FAPI radiotracer

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-FAPI and 18F-AlF-FAPI PET-MR
Description: Hybrid Cardiac PET-MR with 68Ga-FAPI and 18F-AlF-FAPI radiotracer
Study: NCT06478706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETD001
Description: Twice daily doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETD001
Description: Twice daily doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Twice daily doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Twice daily doses
Study: NCT06491823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory adaptation in speech
Study: NCT06203275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: intervention group n=22 Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus paroxetine 12.5 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus placebo daily
Study: NCT06443541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-intensity implementation strategies (LIS) Implementation Team Members
Description: * Passive access to web-based educational materials~* In-person technical training on campus-wide implementation of GlobalConsent; discussion and demonstration of GlobalConsent program; standardized implementation manual
Study: NCT06491823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation baseline
Description: Auditory baseline in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation baseline
Description: Auditory baseline in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation baseline
Description: Auditory baseline in speech

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motor evoked potentials
Description: motor evoked potentials will be obtained in each recording block

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motor evoked potentials
Description: motor evoked potentials will be obtained in each recording block

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory evoked potentials
Description: auditory evoked potentials will be obtained in each recording block
Study: NCT06491823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory evoked potentials
Description: auditory evoked potentials will be obtained in each recording block

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potentials
Description: Somatosensry evoked potentials will be obtained in each recording block

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potentials
Description: Somatosensry evoked potentials will be obtained in each recording block
Study: NCT06259903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD-18
Description: Subcutaneous Administration of MD-18 in Healthy Subjects.
Study: NCT05889052

Intervention type: DRUG
Intervention: Sulfadoxine pyrimethamine
Description: Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)

Intervention type: DRUG
Intervention: Sulfadoxine pyrimethamine
Description: Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
Study: NCT05140291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: 1/2 needles will placed into defined innervation fields of the trigeminal nerve and rotated. Total time will be 5-7 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Dry Needling
Description: Needle handles inside of guide tubes will be tapped in a way similar to an actual needle being set but the sham needles will be blunted.
Study: NCT03924778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH diet
Description: brief description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard American diet
Description: describe
Study: NCT05414812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component oncofertility care intervention
Description: The intervention includes:~1. Young breast cancer patients presenting to oncology visits will complete a clinic-based oncofertility needs screen with a member of the clinical team. This needs screen assesses i) desire to have a child in the future, ii) need for contraception, and iii) sexual health/menopause symptoms.~2. A women's health survivorship care plan (SCP) in Spanish and English encompasses content on screening and management strategies for a) fertility concerns/pregnancy health; b) contraception; c) hot flashes and d) sexual health.~3. Oncofertility navigation consists of one telehealth or in-person session with a social worker to: i) assess the patient's oncofertility needs, ii) review the women's health SCP, iii) provide support with the goal of engaging in oncofertility care.~4. Oncofertility consultation as indicated via telehealth or in person will occur between the patient and reproductive specialist. Each consultation is estimated to be 1 hour.
Study: NCT06572618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography and Computed Tomography Scan
Description: Undergo PET-CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT04711356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection
Description: Ad26.ZEBOV is a monovalent, replication-incompetent adenovirus serotype 26-based vector that expresses the full-length Ebola virus Mayinga glycoprotein
Study: NCT05580783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal labelled with 54Fe
Description: Each participant will receive 2 test meals containing 4mg each of isotopic tracer 54Fe

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal labelled with 57Fe
Description: Each participant will receive 2 test meals containing 4mg each of isotopic tracer 57Fe

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal labelled with 58Fe
Description: Each participant will receive 2 test meals containing 4mg each of isotopic tracer 58Fe
Study: NCT05985109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: KN046 is a recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: KN046 is a recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: KN046 is a recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: Regorafenib is a multi-target tyrosine kinase inhibitors and is one of the standard third-line therapy in mCRC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: Regorafenib is a multi-target tyrosine kinase inhibitors and is one of the standard third-line therapy in mCRC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: Regorafenib is a multi-target tyrosine kinase inhibitors and is one of the standard third-line therapy in mCRC
Study: NCT04783987

Intervention type: OTHER
Intervention: Walking asessments
Description: Gait parameters will be evaluated in single and dual task conditions with 10 Meter Walk Test and wireless digital miniature portable walking and movement analyzer.

Intervention type: OTHER
Intervention: Walking asessments
Description: Gait parameters will be evaluated in single and dual task conditions with 10 Meter Walk Test and wireless digital miniature portable walking and movement analyzer.
Study: NCT05272787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TH Facial Moisturizer
Description: All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TH Facial Moisturizer
Description: All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
Study: NCT04277611

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcostal Oblique Quadratus Lumborum Block and Erector Spinae Plain Block.
Description: patients undergo general anesthesia,will be put in prone position.In case of Quadratus Lumborum block 1-3 mL of normal saline is injected to produce hydro-dissection and spread cranially between the QL and kidney. The corresponding ultrasonographic sign is a lunar-shaped hypo-echoic fluid collection observed between the long axis of the kidney and QL muscle. 20 ml Bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is administered. In case of the ESPB The location of the needle tip is confirmed by hydro-dissection and after visualizing the fluid spread lifting the Erector Spinae off the transverse process, 20 ml bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcostal Oblique Quadratus Lumborum Block and Erector Spinae Plain Block.
Description: patients undergo general anesthesia,will be put in prone position.In case of Quadratus Lumborum block 1-3 mL of normal saline is injected to produce hydro-dissection and spread cranially between the QL and kidney. The corresponding ultrasonographic sign is a lunar-shaped hypo-echoic fluid collection observed between the long axis of the kidney and QL muscle. 20 ml Bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is administered. In case of the ESPB The location of the needle tip is confirmed by hydro-dissection and after visualizing the fluid spread lifting the Erector Spinae off the transverse process, 20 ml bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is injected.
Study: NCT06449716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-week progressive power-oriented resistance exercise program
Description: 2x/week, 35-45 min sessions, on leg press machine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12-week progressive power-oriented resistance exercise program
Description: 2x/week, 35-45 min sessions, on leg press machine
Study: NCT05888779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage One (Milk)
Description: Participant will consume beverage one (milk) and complete novel cognitive assessment questionnaire on paper.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage Two (Juice)
Description: Participant will consume beverage two (fruit drink) and complete novel cognitive assessment questionnaire on paper.
Study: NCT04731415

Intervention type: DEVICE
Group type: OTHER
Intervention: Optical coherence tomography and optical coherence tomography angiography (Optovue®)
Description: Optical coherence tomography and optical coherence tomography angiography (Optovue®) were performed in each trimesters and at 6 weeks after childbirth.~1. st trimester : gestational age 8-12 weeks~2. nd trimester : gestational age 24-28 weeks~3. rd trimester : gestational age 34-38 weeks
Study: NCT06533098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIG)
Description: IVIG will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered orally.
Study: NCT06510530

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astragalus
Description: Patients in the intervention group will receive capsules of the Astragalus plant (scientific name: Astragalus membranaceus, common name: Huang Qi) at an initial dose of 2 grams (4 capsules) per day with the option of increasing the dose to 4 grams (8 capsules) per day according to researchers' assessment and patient tolerance. The dose was determined by a focus group of 5 herbalists and according to data from the literature on oncology patients. The duration of the treatment will be up to a month from the end of the chemotherapy treatment which usually lasts up to six months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules that look similar to Astragalus capsules will be given to patients from the control group, between 4 and 8 capsules per day according to the researcher's assessment and tolerability. The duration of the treatment will be up to a month from the end of the chemotherapy treatment which usually lasts up to six months.
Study: NCT06486948

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CT-156
Description: CT-156 is a digital therapeutic (DTx) under development to treat patients 18 years of age and older with a diagnosis of schizophrenia under standard of care therapy who are on antipsychotic medication and not currently experiencing acute hallucinations or delusions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT-156
Description: CT-156 is a digital therapeutic (DTx) under development to treat patients 18 years of age and older with a diagnosis of schizophrenia under standard of care therapy who are on antipsychotic medication and not currently experiencing acute hallucinations or delusions.
Study: NCT05418764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Miyamodel Training
Description: standardized training by performing five hysterectomies on the Miyamodel with a trainer who is a sub-PI at each institution
Study: NCT04935814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin, Arginine
Description: Once vasopressin infusion started, patients positions will be randomized: Trendelenburg (-30°), anti Trendelenburg (+30°) and supine position (0°).
Study: NCT05438186

Intervention type: DRUG
Intervention: Liraglutide
Description: Participants with obesity who received initial prescription of Saxenda® (liragltuide 3.0 milligrams (mg) once daily)) and maintained treatment with Saxenda® for at least 16 weeks, without treatment break, following the initial prescription for weight management.
Study: NCT05272787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TH Lip Moisturizer
Description: All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TH Lip Moisturizer
Description: All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Moisturizer B (Control)
Description: All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.